Invitro drug-drug interactions of decitabine and tetrahydrouridine involving drug transporters and drug metabolising enzymes

References

• Abboud MR. 2020. Standard management of sickle cell disease complications. Hematol Oncol Stem Cell Ther. 13(2):85–90.
   PubMedGoogle Scholar
• Arimany-Nardi C, Errasti-Murugarren E, Minuesa G, Martinez-Picado J, Gorboulev V, Koepsell H, Pastor-Anglada M. 2014. Nucleoside transporters and human organic cation transporter 1 determine the cellular handling of DNA-methyltransferase inhibitors. Br J Pharmacol. 171(16):3868–3880.
   PubMed Web of Science ®Google Scholar
• Beumer JH, Eiseman JL, Parise RA, Florian JA Jr., Joseph E, D'Argenio DZ, Parker RS, Kay B, Covey JM, Egorin MJ. 2008a. Plasma pharmacokinetics and oral bioavailability of 3,4,5,6-tetrahydrouridine, a cytidine deaminase inhibitor, in mice. Cancer Chemother Pharmacol. 62(3):457–464.
   PubMed Web of Science ®Google Scholar
• Beumer JH, Parise RA, Newman EM, Doroshow JH, Synold TW, Lenz HJ, Egorin MJ. 2008b. Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2′-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU). Cancer Chemother Pharmacol. 62(2):363–368.
   PubMed Web of Science ®Google Scholar
• CDC. 2020. Data & statistics on sickle cell disease; [accessed 2021 Jan 12]. https://www.cdc.gov/ncbddd/sicklecell/data.html
   Google Scholar
• Charache S, Dover G, Smith K, Talbot CC Jr., Moyer M, Boyer S. 1983. Treatment of sickle cell anemia with 5-azacytidine results in increased fetal hemoglobin production and is associated with nonrandom hypomethylation of DNA around the gamma-delta-beta-globin gene complex. Proc Natl Acad Sci USA. 80(15):4842–4846.
   PubMed Web of Science ®Google Scholar
• Cohen RM, Wolfenden R. 1971. Cytidine deaminase from Escherichia coli: purification, properties and inhibition by the potential transition state analog 3,4,5,6-tetrahydrouridine. J Biol Chem. 246(24):7561–7565.
   PubMed Web of Science ®Google Scholar
• Damaraju VL, Mowles D, Yao S, Ng A, Young JD, Cass CE, Tong Z. 2012. Role of human nucleoside transporters in the uptake and cytotoxicity of azacitidine and decitabine. Nucleosides Nucleotides Nucleic Acids. 31(3):236–255.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, Frankfurt O, Konopleva M, Wei AH, Kantarjian HM, et al. 2019. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 133(1):7–17.
   PubMed Web of Science ®Google Scholar
• EMA. 2008. Hydroxycarbamide (Siklos) EPAR – product information; [accessed 2020 Nov 24]. https://www.ema.europa.eu/en/documents/product-information/siklos-epar-product-information_en.pdf
   Google Scholar
• EMA. 2012a. Dacogen Assessment report (EMA/620205/2012); [accessed 2020 Nov 18]. https://www.ema.europa.eu/en/documents/assessment-report/dacogen-epar-public-assessment-report_en.pdf
   Google Scholar
• EMA. 2012b. Guideline on the investigation of drug interactions (CPMP/EWP/560/95/Rev. 1 Corr. 2); [accessed 2020 Nov 24]. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-drug-interactions-revision-1_en.pdf
   Google Scholar
• EMA. 2017. Public summary of opinion on orphan designation – decitabine and tetrahydrouridine for the treatment of sickle cell disease (EMA/324973/2017); [accessed 2021 Jan 12]. https://www.ema.europa.eu/en/documents/orphan-designation/eu/3/17/1881-public-summary-opinion-orphan-designation-decitabine-tetrahydrouridine-treatment-sickle-cell_en.pdf
   Google Scholar
• EMA. 2019. Decitabine (Dacogen®): EPAR – product information; [accessed 2021 Jan 13]. https://www.ema.europa.eu/en/documents/product-information/dacogen-epar-product-information_en.pdf
   Google Scholar
• EMA. 2021. Crizanlizumab (Adakveo) – EPAR product information; [accessed 2021 Jan 12]. https://www.ema.europa.eu/en/documents/product-information/adakveo-epar-product-information_en.pdf
   Google Scholar
• FDA. 2017. L-glutamine (EndariTM) – prescribing information; [accessed 2020 Nov 24]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208587s000lbl.pdf
   Google Scholar
• FDA. 2018. Decitabine (DACOGEN®) – prescribing information; [accessed 2021 Jan 13]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021790s021lbl.pdf
   Google Scholar
• FDA. 2019a. Crizanlizumab-tmca (ADAKVEO®) – prescribing information; [accessed 2021 May 5]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761128s000lbl.pdf
   Google Scholar
• FDA. 2019b. Venetoclax (VENCLEXTA®) – prescribing information; [accessed 2021 Nov 10]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208573s013lbl.pdf
   Google Scholar
• FDA. 2019c. Voxelotor (OXBRYTA™) – prescribing information; [accessed 2020 Nov 24]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213137s000lbl.pdf
   Google Scholar
• FDA. 2020. In vitro drug interaction studies – cytochrome P450 enzyme and transporter-mediated drug interactions – guidance for industry; [accessed 2020 Nov 24]. https://www.fda.gov/media/134582/download
   Google Scholar
• Giacomini KM, Huang S-M, Tweedie DJ, Benet LZ, Brouwer KLR, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, et al. 2010. Membrane transporters in drug development. Nat Rev Drug Discov. 9(3):215–236.
   PubMed Web of Science ®Google Scholar
• Govindarajan R, Bakken AH, Hudkins KL, Lai Y, Casado FJ, Pastor-Anglada M, Tse CM, Hayashi J, Unadkat JD. 2007. In situ hybridization and immunolocalization of concentrative and equilibrative nucleoside transporters in the human intestine, liver, kidneys, and placenta. Am J Physiol Regul Integr Comp Physiol. 293(5):R1809–R1822.
   PubMed Web of Science ®Google Scholar
• Jordheim LP, Durantel D, Zoulim F, Dumontet C. 2013. Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. Nat Rev Drug Discov. 12(6):447–464.
   PubMed Web of Science ®Google Scholar
• Kato GJ, Piel FB, Reid CD, Gaston MH, Ohene-Frempong K, Krishnamurti L, Smith WR, Panepinto JA, Weatherall DJ, Costa FF, et al. 2018. Sickle cell disease. Nat Rev Dis Primers. 4:18010.
   PubMed Web of Science ®Google Scholar
• Kreis W, Budman DR, Chan K, Allen SL, Schulman P, Lichtman S, Weiselberg L, Schuster M, Freeman J, Akerman S, et al. 1991. Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)–a pilot study. Leukemia. 5(11):991–998.
   PubMed Web of Science ®Google Scholar
• Lavelle D, Vaitkus K, Ling Y, Ruiz MA, Mahfouz R, Ng KP, Negrotto S, Smith N, Terse P, Engelke KJ, et al. 2012. Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine. Blood. 119(5):1240–1247.
   PubMed Web of Science ®Google Scholar
• Liang Y, Li S, Chen L. 2015. The physiological role of drug transporters. Protein Cell. 6(5):334–350.
   PubMed Web of Science ®Google Scholar
• Manwani D, Frenette PS. 2013. Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies. Blood. 122(24):3892–3898.
   PubMed Web of Science ®Google Scholar
• Marsh JH, Kreis W, Barile B, Akerman S, Schulman P, Allen SL, DeMarco LC, Schuster MW, Budman DR. 1993. Therapy of refractory/relapsed acute myeloid leukemia and blast crisis of chronic myeloid leukemia with the combination of cytosine arabinoside, tetrahydrouridine, and carboplatin. Cancer Chemother Pharmacol. 31(6):481–484.
   PubMed Web of Science ®Google Scholar
• Molokie R, Lavelle D, Gowhari M, Pacini M, Krauz L, Hassan J, Ibanez V, Ruiz MA, Ng KP, Woost P, et al. 2017. Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: a randomized phase 1 study. PLoS Med. 14(9):e1002382.
   PubMed Web of Science ®Google Scholar
• Paikari A, Sheehan VA. 2018. Fetal haemoglobin induction in sickle cell disease. Br J Haematol. 180(2):189–200.
   PubMed Web of Science ®Google Scholar
• Piel FB, Steinberg MH, Rees DC. 2017. Sickle cell disease. N Engl J Med. 376(16):1561–1573.
   PubMed Web of Science ®Google Scholar
• Saunthararajah Y. 2019. Targeting sickle cell disease root-cause pathophysiology with small molecules. Haematologica. 104(9):1720–1730.
   PubMed Web of Science ®Google Scholar
• Steinberg MH, Chui DH, Dover GJ, Sebastiani P, Alsultan A. 2014. Fetal hemoglobin in sickle cell anemia: a glass half full? Blood. 123(4):481–485.
   PubMed Web of Science ®Google Scholar
• Varga A, Lionne C, Roy B. 2016. Intracellular metabolism of nucleoside/nucleotide analogues: a bottleneck to reach active drugs on HIV reverse transcriptase. Curr Drug Metab. 17(3):237–252.
   PubMed Web of Science ®Google Scholar